High-quality evidence generated by appropriately powered and controlled trials is needed to advance care for patients with coronavirus disease 2019 (COVID-19) and those who are susceptible to it.
1,2 In the midst of the COVID-19 pandemic, multiple similar therapeutic trials are being conducted in parallel, potentially reducing participant accrual across trials. In this systematic review, we characterize the landscape of current COVID-19 trials to better quantify these potential issues.